author-photo

Andrew Blauvelt

Oregon Health & Science University

460

Papers

15659

Citations

Citation Trend

Filter By

Papers (289) Sort By

Journal Conference Others

25750 Tapinarof cream 1% once daily for plaque psoriasis: Secondary efficacy outcomes from two pivotal phase 3 trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (1)
Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

2021
Show All
- Source
- Cite
- Save
Citations (0)
27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

2021
Show All
- Source
- Cite
- Save
Citations (1)
Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.

2021 Journal of Managed Care Pharmacy
Show All
- Source
- Cite
- Save
Citations (0)
26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
27383 Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials

2021
Show All
- Source
- Cite
- Save
Citations (0)
Bimekizumab versus Adalimumab in Plaque Psoriasis.

2021 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (13)
Consistent safety profile with up to five years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (1)